Yuanfei Fu

Yuanfei Fu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Neuropharmacology
Verified
Journal Article
Open access
ZHZhenyu Huang
Zhenyu Huang
HTHaibo Tan
Haibo Tan
YFYuanfei Fu
Yuanfei Fu
HXHuanxin Xie
Huanxin Xie
HTHuangsheng Tan
Huangsheng Tan
HLHongkan Lou
Hongkan Lou
Chronic pain due to lumbar disc herniation (LDH) significantly impairs quality of life and is often accompanied by emotional disturbances, such as anxiety and depression. Despite the recognition of these comorbidities, the underlying neural mechanisms remain unclear. This study investigates the role of neurotransmitter imbalances and key regulatory molecules in LDH-induced chronic pain and related emotional disturbances, with a focus on synaptic plasticity in the amygdala. A rat model of LDH was developed using male Sprague-Dawley rats. Behavioral assessments were conducted to evaluate pain hypersensitivity, anxiety, and depression-like behaviors. Cerebrospinal fluid (CSF) metabolomics and amygdala transcriptomics were employed to analyze neurotransmitter profiles and gene expression. In vitro experiments were conducted to explore the role of PRKCG in synaptic plasticity. Behavioral tests showed significant pain hypersensitivity and anxiety- and depression-like behavior in LDH rats. Metabolomic analysis revealed altered levels of glutamate and γ-aminobutyric acid (GABA) in the CSF, indicating neurotransmitter imbalances. Transcriptomic profiling identified changes in genes related to synaptic plasticity, including PRKCG. PRKCG knockdown led to reduced CAMKII phosphorylation and GRIA1 expression, supporting its role in modulating synaptic plasticity. This study provides evidence that neurotransmitter imbalances and alterations in synaptic plasticity within the amygdala may contribute to the persistence of chronic pain and associated emotional disturbances in LDH. PRKCG may represent a novel therapeutic target for treating both chronic pain and related emotional disturbances.

29 August 2025 in Neuropharmacology
Verified
Journal Article
Closed access
ZHZhenyu Huang
Zhenyu Huang
JSJiawen Sun
Jiawen Sun
HLHaokang Li
Haokang Li
ZHZhuang Hu
Zhuang Hu
HTHaibo Tan
Haibo Tan
HLHongkan Lou
Hongkan Lou

20 June 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
HTHuangsheng Tan
Huangsheng Tan
XGXinhai Gao
Xinhai Gao
CDChengcai Dai
Chengcai Dai
PSPan Shen
Pan Shen
JLJuyi Lai
Juyi Lai
SHShenghua He
Shenghua He
Objective: To explore the complex interactions between gut microbiota and immune cell phenotypes in rheumatoid arthritis development and identify potential therapeutic targets within the gut microbiota–immune cell axis. Methods: We conducted a Mendelian randomization analysis to explore the causal relationship between gut microbiota and rheumatoid arthritis, including the role of immune cell mediators. Sensitivity analyses assessed pleiotropy and heterogeneity, while mediation analysis identified pathways through which immune cells mediate gut microbiota effects on rheumatoid arthritis development. Key microbial taxa and their effects on rheumatoid arthritis were quantified. Results: Our analysis identified 27 gut microbiota taxa significantly associated with rheumatoid arthritis, with Provencibacterium massiliense showing the strongest protective effect (odds ratio = 0.807, 95% confidence interval: 0.700–0.911, P = 0.003). Additionally, 20 immune cell phenotypes with IgD+ CD38dim AC were significantly linked to rheumatoid arthritis (odds ratio = 1.064, 95% confidence interval: 1.027–1.102). Mediation analysis uncovered 13 significant gut microbiota–immune cell pathways, with the UBA8517–CCR2 monocyte pathway mediating 10.1% of the total effect (beta1 = −0.595, beta12 = 0.027, mediation proportion = 10.1%). Conclusion: This study offers novel insights into the gut microbiota–immune cell axis in rheumatoid arthritis, identifying Provencibacterium massiliense , IgD+ CD38dim AC and the UBA8517—CCR2 monocyte pathway as potential therapeutic targets for rheumatoid arthritis treatment.

14 August 2025
Verified
Journal Article
Open access
JLJuyi Lai
Juyi Lai
XLXinbei Li
Xinbei Li
HTHuangsheng Tan
Huangsheng Tan
HFHualong Feng
Hualong Feng
ZLZhi Ming Lan
Zhi Ming Lan
SHShenghua He
Shenghua He
This study aimed to investigate the impact of sarcopenia on the clinical outcomes of patients undergoing posterior surgical treatment for degenerative lumbar scoliosis. A retrospective analysis was conducted on clinical data from 76 patients with degenerative lumbar scoliosis, who meet the selection criteria between January 2019 and December 2023. The patients were categorized into a sarcopenia group (31 cases) and a non-sarcopenia group (45 cases) based on the diagnostic criteria of the European Working Group on Sarcopenia in Older People (EWGSOP). Operative time, intraoperative blood loss, hospital stay duration, incision length, incision healing time, and complications were compared between the sarcopenia and non-sarcopenia groups. The improvement in clinical symptoms was evaluated using the Visual Analog Scale (VAS) and the Oswestry Disability Index (ODI). To assess the scoliosis correction effect, measurements were taken for the coronal Cobb angle (CCA), C7 plumb line-center sacral vertical line (C7-CSVL), lumbar lordosis (LL), and C7 plumb line-sagittal vertical axis (C7-SVA). All patients successfully underwent the surgical procedure. The average operation time in the sarcopenia group was 256.27 ± 28.09 (180-350) min, which was not significantly different from the 249.82 ± 24.35(185-320) min in the non-sarcopenia group (p > 0.05). The average intraoperative blood loss in the sarcopenia group was 786.25 ± 38.19 (420-1365) mL, compared to 810.62 ± 45.47 (456-1780) mL in the non-sarcopenia group (p > 0.05). The average incision length in the sarcopenia group was 12.57 ± 1.29 (10-16)cm, compared to 12.83 ± 2.03 (9-20)cm in the non-sarcopenia group (p > 0.05). The incision healing time in the sarcopenia group required an average of 15.72 ± 1.74 (12-25)d, which longer than the 10.18 ± 1.05 (10-14 ) d in the non-sarcopenia group (p < 0.05). The average hospital stay in the sarcopenia group was 13.46 ± 1.37 (8-26) d, which was also longer than the 8.33 ± 0.92 (6-12)d in the non-sarcopenia group (p < 0.05). The complication rate in the sarcopenia group was 29.03% (9/31), which was higher than the 13.33% (6/45) in the non-sarcopenia group (p < 0.05). The VAS and ODI scores of both groups at the last follow-up were significantly improved compared to preoperative levels (p < 0.05). At the last follow-up, the ODI in the non-sarcopenia group was better than that in the sarcopenia group (p < 0.05). There was no statistically significant difference between the two groups in terms of VAS scores at the last follow-up (p > 0.05). Both groups demonstrated significant improvements in CCA, C7-CSVL, LL, and C7-SVA compared to preoperative levels (p < 0.05). However, no statistically significant differences were observed between the groups at the final follow-up (p > 0.05). Sarcopenia does not significantly affect the radiological outcomes of patients with degenerative lumbar scoliosis undergoing posterior surgical procedures, ODI was better in the non-sarcopenia group. In addition, patients with sarcopenia typically require a longer postoperative recovery period and are more susceptible to various complications compared to those without sarcopenia.

14 November 2026 in Molecules
Verified
Journal Article
Open access
PDF file
PDPengwei Deng
Pengwei Deng
HTHuangsheng Tan
Huangsheng Tan
WXWeijun Xu
Weijun Xu
YFYuanfei Fu
Yuanfei Fu
SHShenghua He
Shenghua He
Background: Postmenopausal osteoporosis (PMOP) is a systemic metabolic bone disease characterized by impaired microarchitecture and increased fracture risk. Although angiogenesis and programmed cell death (PCD) play essential roles in bone homeostasis, how their associated transcriptional programs relate to PMOP pathogenesis within the bone marrow niche at single-cell and genetic levels remains incompletely defined. Methods: An integrative framework was established combining scRNA-seq, GWAS-derived transcriptome risk scores (scPagwas), bulk transcriptomics and machine learning (LASSO, RF and SVM-RFE with SHAP). WGCNA identified co-expression modules linked to angiogenesis-related genes and dysregulated PCD modes. Candidates were further examined in a second cohort. A two-gene nomogram was constructed in the training cohort. Tissue localisation and scTenifoldKnk virtual knockout were explored, and candidate compounds were assessed by drug-signature enrichment, blind docking and 100-ns molecular dynamics (MD). Results: Single-cell profiling categorized 11 distinct cell types in the osteoporotic microenvironment, with neutrophils and fibroblasts constituting the predominant populations. ScPagwas analysis identified 1169 TRS-associated candidate DEGs, which were enriched in osteoclast differentiation and myeloid cell lineage pathways. Intersection across scPagwas-DEGs, ARDEGs, and PCD-WGCNA modules yielded candidate targets, from which EGFL7 and PROC were prioritized as dual-feature hub biomarkers. Both hub genes exhibited consistent upregulation in PMOP and the two-gene nomogram showed an apparent AUC of 0.800 (95% CI 0.658–0.942). Exploratory ssGSEA of 28 immune cell-related gene sets in the monocyte cohort identified four gene sets that differed between groups after Benjamini–Hochberg correction and showed weak correlations with EGFL7 and PROC. Virtual knockout (scTenifoldKnk) of PROC in pDCs and EGFL7 in ProB cells predicted perturbations of chronic inflammatory and translational programmes. Drug-signature enrichment nominated norgestimate as the top-ranked compound for the PROC expression signature; blind docking (−8.3 kcal/mol) and 100-ns MD indicated that the predicted pose remained stable over the trajectory. Conclusion: This study presents an integrative single-cell and multi-omics framework linking angiogenic and programmed-cell-death programmes in PMOP at single-cell and genetic resolution, and nominates EGFL7 and PROC as candidate dual-feature biomarkers with cell-type-specific localisation. It further generates a structural hypothesis for a PROC–norgestimate interaction, providing a concrete starting point for target validation and drug repurposing in PMOP. These findings are exploratory and await experimental validation.